Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update

Author's Avatar
May 11, 2023

Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors